Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2017 | Do we need to stratify follicular lymphoma (FL) patients for treatment?

Jessica Okosun • 27 Mar 2017
BSH 2017
Follicular Lymphoma Bendamustine Rituximab

Jessica Okosun, MA, MB, BChir, PhD, MRCP, FRCPath of Barts Cancer Institute, London, UK, discusses the follicular lymphoma (FL) treatment landscape at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. She explains the standard of care in the UK, and highlights that despite patient heterogeneity, all patients receive the same chemoimmunotherapy. Dr Okosun argues that the underlying biological heterogeneity means patients should be stratified rather than using the same treatment for all patients.

More from Jessica Okosun

Early screening in lymphoma: current perspectives & future outlooks
Jessica Okosun et al. • 25 Mar 2024
3:46
The relevance of follicular lymphoma pathogenesis in clinical practice
Jessica Okosun • 6 Sep 2021
2:13
MRD for decision making in follicular lymphoma
Jessica Okosun • 6 Sep 2021
1:47
The influence of the TME on progression and outcomes in follicular lymphoma
Jessica Okosun • 6 Sep 2021

Related Videos

1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
1:48
Novel immunotherapy approaches in lymphoma: CAR-T cells, bispecifics & sequencing
Gloria Iacoboni • 15 Apr 2024
0:55
Mosunetuzumab in untreated FL and MZL: a response-adapted trial
Ryan Lynch • 8 Dec 2023
3:32
BGB-16673, a novel BTK degrader, in patients with R/R B-cell malignancies
John Seymour • 8 Dec 2023
The content of VJHemOnc is intended for healthcare professionals